The EndoPredict score predicts residual cancer burden after neoadjuvant chemotherapy and after neoendocrince therapy in HR+/HER2-breast cancer patients from ABCSG 34

PC Dubsky; C Fesl; CF Singer; G Pfeiler; R Kronenwett; M Hubalek; R Bartsch; H Stoeger; A Pichler; E Petru; V Bjelic-Radisic; Richard Greil; M Rudas; MKM Tea; V Wette; AL Petzner; P Sevelda; D Egle; F Fitzal; R Exner; R Jakesz; M Balic; C Tinchon; Z Bago-Horvath; S Lax; P Regitnig; M Gnant; M Filipits

The EndoPredict score predicts residual cancer burden after neoadjuvant chemotherapy and after neoendocrince therapy in HR+/HER2-breast cancer patients from ABCSG 34

PC Dubsky, C Fesl, CF Singer, G Pfeiler, R Kronenwett, M Hubalek, R Bartsch, H Stoeger, A Pichler, E Petru, V Bjelic-Radisic, Richard Greil, M Rudas, MKM Tea, V Wette, AL Petzner, P Sevelda, D Egle, F Fitzal, R ExnerR Jakesz, M Balic, C Tinchon, Z Bago-Horvath, S Lax, P Regitnig, M Gnant, M Filipits

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Abstract (Journal) › peer-review

2 Citations (Web of Science)

Original language	English
Journal	CANCER RESEARCH
Volume	78
Issue number	4
Publication status	Published - 2018
Event	San Antonio Breast Cancer Symposium - San Antonio, TX Duration: 5 Dec 2017 → 9 Dec 2017

Cite this

Dubsky, PC., Fesl, C., Singer, CF., Pfeiler, G., Kronenwett, R., Hubalek, M., Bartsch, R., Stoeger, H., Pichler, A., Petru, E., Bjelic-Radisic, V., Greil, R., Rudas, M., Tea, MKM., Wette, V., Petzner, AL., Sevelda, P., Egle, D., Fitzal, F., ... Filipits, M. (2018). The EndoPredict score predicts residual cancer burden after neoadjuvant chemotherapy and after neoendocrince therapy in HR+/HER2-breast cancer patients from ABCSG 34. CANCER RESEARCH , 78(4).

Dubsky, PC ; Fesl, C ; Singer, CF et al. / The EndoPredict score predicts residual cancer burden after neoadjuvant chemotherapy and after neoendocrince therapy in HR+/HER2-breast cancer patients from ABCSG 34. In: CANCER RESEARCH 2018 ; Vol. 78, No. 4.

@article{05f440cc00dc472a98e6125f8ffb21ef,

title = "The EndoPredict score predicts residual cancer burden after neoadjuvant chemotherapy and after neoendocrince therapy in HR+/HER2-breast cancer patients from ABCSG 34",

author = "PC Dubsky and C Fesl and CF Singer and G Pfeiler and R Kronenwett and M Hubalek and R Bartsch and H Stoeger and A Pichler and E Petru and V Bjelic-Radisic and Richard Greil and M Rudas and MKM Tea and V Wette and AL Petzner and P Sevelda and D Egle and F Fitzal and R Exner and R Jakesz and M Balic and C Tinchon and Z Bago-Horvath and S Lax and P Regitnig and M Gnant and M Filipits",

year = "2018",

language = "English",

volume = "78",

journal = "CANCER RESEARCH ",

issn = "0008-5472",

publisher = "Amer Assoc Cancer Research",

number = "4",

note = "San Antonio Breast Cancer Symposium ; Conference date: 05-12-2017 Through 09-12-2017",

}

Dubsky, PC, Fesl, C, Singer, CF, Pfeiler, G, Kronenwett, R, Hubalek, M, Bartsch, R, Stoeger, H, Pichler, A, Petru, E, Bjelic-Radisic, V, Greil, R, Rudas, M, Tea, MKM, Wette, V, Petzner, AL, Sevelda, P, Egle, D, Fitzal, F, Exner, R, Jakesz, R, Balic, M, Tinchon, C, Bago-Horvath, Z, Lax, S, Regitnig, P, Gnant, M & Filipits, M 2018, 'The EndoPredict score predicts residual cancer burden after neoadjuvant chemotherapy and after neoendocrince therapy in HR+/HER2-breast cancer patients from ABCSG 34', CANCER RESEARCH , vol. 78, no. 4.

The EndoPredict score predicts residual cancer burden after neoadjuvant chemotherapy and after neoendocrince therapy in HR+/HER2-breast cancer patients from ABCSG 34. / Dubsky, PC; Fesl, C; Singer, CF et al.
In: CANCER RESEARCH , Vol. 78, No. 4, 2018.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - The EndoPredict score predicts residual cancer burden after neoadjuvant chemotherapy and after neoendocrince therapy in HR+/HER2-breast cancer patients from ABCSG 34

AU - Dubsky, PC

AU - Fesl, C

AU - Singer, CF

AU - Pfeiler, G

AU - Kronenwett, R

AU - Hubalek, M

AU - Bartsch, R

AU - Stoeger, H

AU - Pichler, A

AU - Petru, E

AU - Bjelic-Radisic, V

AU - Greil, Richard

AU - Rudas, M

AU - Tea, MKM

AU - Wette, V

AU - Petzner, AL

AU - Sevelda, P

AU - Egle, D

AU - Fitzal, F

AU - Exner, R

AU - Jakesz, R

AU - Balic, M

AU - Tinchon, C

AU - Bago-Horvath, Z

AU - Lax, S

AU - Regitnig, P

AU - Gnant, M

AU - Filipits, M

PY - 2018

Y1 - 2018

M3 - Abstract (Journal)

SN - 0008-5472

VL - 78

JO - CANCER RESEARCH

JF - CANCER RESEARCH

IS - 4

T2 - San Antonio Breast Cancer Symposium

Y2 - 5 December 2017 through 9 December 2017

ER -

Dubsky PC, Fesl C, Singer CF, Pfeiler G, Kronenwett R, Hubalek M et al. The EndoPredict score predicts residual cancer burden after neoadjuvant chemotherapy and after neoendocrince therapy in HR+/HER2-breast cancer patients from ABCSG 34. CANCER RESEARCH . 2018;78(4).